FDA adds a cardiovascular indication to Mounjaro for people with type 2 diabetes
The new indication covers adults with type 2 diabetes at high risk of a heart attack or stroke. In the four-year trial behind it, 13,299 people took either tirzepatide or dulaglutide, an older drug that already carried a heart indication, and the two performed about the same.
Tirzepatide, sold as Mounjaro, is the drug behind a great deal of the current interest in metabolic medicine, and until late August its approved uses were about blood sugar and weight. On 27 August 2026 the FDA added a second kind of claim to the label: reducing the risk of cardiovascular death, a non-fatal heart attack or a non-fatal stroke. It is the first drug of its class, a dual GIP and GLP-1 receptor agonist, to carry one.
That matters because a label is the boundary of what anyone may say about a medicine, and heart outcomes are the thing patients care about most. It is also worth understanding what the trial behind it did and did not settle, because the comparison it ran was an unusual one and the answer is more interesting than a yes or a no.
Done in people, which is the setting that counts. It still matters who was studied, how many, and for how long.
An action by a regulator, such as approving a use or adding a warning. It reflects evidence an agency reviewed, and it is a decision about what may be sold and claimed rather than a new result.
Published by a regulatory agency, such as an approval notice, a safety communication or a review document.
Adults with type 2 diabetes and established atherosclerotic cardiovascular disease, 40 and older. Mean age 64.
Randomized, double-blind trial against an active comparator, dulaglutide, rather than against a placebo. Built to test whether tirzepatide is not meaningfully worse.
13,299 adults, 6,647 in each group. Median follow-up 210.1 weeks, about four years.
Eli Lilly and Company, which makes tirzepatide and also makes dulaglutide, the comparator.
Not established from the material reviewed here. The approval letter and the label carry no author disclosures; the trial publication does, and it sits behind a paywall.
What the FDA approved
The approval letter names one trial, SURPASS-CVOT, and the new indication now appears in the approved prescribing information. Most cardiovascular outcome trials compare a new drug against a placebo. This one did not. It randomized 13,299 adults who had type 2 diabetes and established cardiovascular disease to weekly tirzepatide or weekly dulaglutide, an older GLP-1 that already carries its own cardiovascular indication, and followed them for a median of 210.1 weeks, a little over four years.
The question a trial like that is built to answer is not "is the new drug better". It is "is the new drug not meaningfully worse than one we already trust". Researchers call that a non-inferiority trial, and it is a different question with a different answer.
What happened to the people in it
Over those four years, the combined outcome of cardiovascular death, non-fatal heart attack or non-fatal stroke happened to about 12 people in every 100 taking tirzepatide and about 13 in every 100 taking dulaglutide. In the label's own counts: 803 of 6,647 against 863 of 6,647.
That gap was enough for the trial to conclude tirzepatide is not meaningfully worse than dulaglutide, which is what it set out to test. It was not enough to establish that tirzepatide is better, and the approved label says so in those words: superiority to dulaglutide was not established. The difference is small and the trial could not tell it apart from chance.
Two rows of a hundred squares. Twelve are filled for tirzepatide and thirteen for dulaglutide.
One line behaves differently. Deaths from any cause were lower on tirzepatide, 567 against 670, or about 8.5 in every 100 against 10.1. That looks like the most striking number on the page, and the label attaches a footnote to it saying it was not controlled for the family-wise type I error rate. In plain terms: it was not one of the questions the trial was designed to answer, and when you measure many things at once some of them look impressive by chance. It is a reason to keep watching, not a finding to rely on.
The statistical detail, for readers who want it
Estimated hazard ratio for time to first major adverse cardiovascular event: 0.92, with a 95.3 percent confidence interval of 0.83 to 1.01. Non-inferiority p = 0.007. The trial set in advance that an upper limit below 1.00 would indicate superiority; the interval's upper end sits just above it, and the published superiority p value is 0.09.
Components, tirzepatide against dulaglutide: cardiovascular death 367 (5.5 percent) against 409 (6.2), hazard ratio 0.89 (0.77 to 1.02); non-fatal heart attack 292 (4.4) against 310 (4.7), 0.93 (0.80 to 1.09); non-fatal stroke 215 (3.2) against 221 (3.3), 0.97 (0.80 to 1.16). All-cause death 567 (8.5) against 670 (10.1), 0.84 (0.75 to 0.94). Every line below the primary outcome carries the label's footnote that it was not controlled for the family-wise type I error rate.
All figures from Table 10 of the approved prescribing information, section 14.6.
Why matching dulaglutide still counts
A trial that fails to prove superiority is easy to read as a trial that found nothing. That would be the wrong reading here, and the reason is the drug on the other side.
Dulaglutide is not a placebo and it is not an inert control. It carries its own cardiovascular indication, earned in its own outcome trial, and it is a treatment a cardiologist would be content to have a patient on. Performing about as well as an established, effective comparator over four years in 13,299 people is a substantial result. It is the difference between a drug that has been shown to be a reasonable choice for this population and a drug about which nothing is known.
What it does not do is rank the two. Anyone who tells you this trial showed tirzepatide protects hearts better than dulaglutide is describing a result the trial did not produce.
Who the new indication covers
Everyone in SURPASS-CVOT had type 2 diabetes and established cardiovascular disease. Their mean age was 64, they had lived with diabetes for about 15 years, and most were already on a statin and an antiplatelet drug. For that group, a clinician now has an approved label to point at for a drug many of them are already taking.
The indication as written is slightly wider than the trial. It reads: in adults with type 2 diabetes who are at high risk for these events. The trial enrolled people who had already had an event or an intervention, which is a narrower and more clearly defined group than "high risk". That gap is worth knowing about, because it is where a label and its evidence stop lining up exactly.
Type 2 diabetes is on both sides of that line. Nobody in this trial was without it, so it says nothing about people taking tirzepatide for weight or for general longevity. The trial also reported more gastrointestinal side effects on tirzepatide, and the same approval added a warning that people with a history of diabetic retinopathy should be monitored for progression.
What to ask if this is on a clinic menu
GLP-1 and dual-incretin prescribing appears throughout this directory, usually for weight. If a program cites heart protection while offering you one, three questions do most of the work. Which population produced that evidence, and does it include people like me. Was the comparison against a placebo or against another active drug. And is the claim that this drug lowers risk, or that it lowers risk more than an alternative, because those rest on different results and this trial only supports the first, in people with diabetes and established heart disease.
Our guide to choosing a longevity clinic covers how to ask those without needing to read a trial.
Sources
- FDA supplement approval letter, NDA 215866/S-044 and S-045 (27 August 2026)
- FDA-approved prescribing information for MOUNJARO (tirzepatide), revised 08/2026. Indication in section 1; trial, population and Table 10 in section 14.6.
- New England Journal of Medicine: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Prepared by the LongevityClinicsHub editorial team. Evidence last checked September 2026. How we research and source these guides.
Enter your ZIP code and we'll point you at the nearest city we've researched.
This report is independent editorial content, written to orient, not to diagnose. It is not medical advice, and a research result is not a treatment you can act on. Where we describe what a company, a clinic or a researcher claims, the claim belongs to them.
Educational reading, not medical advice. Talk to a clinician about your own health.